|
JP5435592B2
(ja)
|
2008-05-28 |
2014-03-05 |
ファイザー・インク |
ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
|
|
NZ599815A
(en)
|
2009-11-10 |
2013-04-26 |
Pfizer |
N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
|
|
ME02330B
(me)
|
2010-03-19 |
2016-06-20 |
Pfizer |
Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
|
|
US9006450B2
(en)
|
2010-07-01 |
2015-04-14 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical compositions and uses thereof
|
|
HUE031616T2
(hu)
|
2010-09-30 |
2017-07-28 |
Pfizer |
N1-pirazol-spiroketon acetil-koenzim-A karboxiláz inhibítorok
|
|
RU2540337C2
(ru)
|
2010-10-29 |
2015-02-10 |
Пфайзер Инк. |
N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
|
|
MY162167A
(en)
|
2011-04-22 |
2017-05-31 |
Pfizer |
Substituted acetyl-coa carboxylase inhibitors
|
|
CA2841757A1
(en)
|
2011-07-15 |
2013-01-24 |
Etzer Darout |
Gpr 119 modulators
|
|
KR20140023441A
(ko)
|
2011-07-22 |
2014-02-26 |
화이자 인코포레이티드 |
퀴놀린일 글루카곤 수용체 조절제
|
|
EP2751116B1
(en)
|
2011-08-31 |
2016-10-12 |
Pfizer Inc |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
JP5731718B2
(ja)
|
2011-11-11 |
2015-06-10 |
ファイザー・インク |
２−チオピリミジノン
|
|
KR20140137404A
(ko)
|
2012-04-06 |
2014-12-02 |
화이자 인코포레이티드 |
디아실글리세롤 아실트랜스퍼라제 2 억제제
|
|
US8889730B2
(en)
|
2012-04-10 |
2014-11-18 |
Pfizer Inc. |
Indole and indazole compounds that activate AMPK
|
|
CA2872154C
(en)
|
2012-05-04 |
2016-08-23 |
Pfizer Inc. |
Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
|
|
EP2897964A1
(en)
|
2012-09-20 |
2015-07-29 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
|
JP2016502978A
(ja)
|
2012-12-11 |
2016-02-01 |
ファイザー・インク |
ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
EP2935282A1
(en)
|
2012-12-19 |
2015-10-28 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
|
WO2014125394A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
RU2016106829A
(ru)
|
2013-09-12 |
2017-10-17 |
Пфайзер Инк. |
Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
|
|
EP3055300B1
(en)
|
2013-10-09 |
2018-03-07 |
Pfizer Inc |
Antagonists of prostaglandin ep3 receptor
|
|
EA032356B1
(ru)
|
2014-03-17 |
2019-05-31 |
Пфайзер Инк. |
Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
|
|
AU2015242291B2
(en)
|
2014-04-04 |
2018-08-30 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds and their use as IRAK4 inhibitors
|
|
SG11201607896YA
(en)
|
2014-04-10 |
2016-10-28 |
Pfizer |
2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
|
|
WO2016041845A1
(en)
*
|
2014-09-17 |
2016-03-24 |
Boehringer Ingelheim International Gmbh |
Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes
|
|
WO2016092413A1
(en)
|
2014-12-10 |
2016-06-16 |
Pfizer Inc. |
Indole and indazole compounds that activate ampk
|
|
JP2017538769A
(ja)
|
2014-12-22 |
2017-12-28 |
ファイザー・インク |
プロスタグランジンｅｐ３受容体の拮抗薬
|
|
JP2018515480A
(ja)
|
2015-05-05 |
2018-06-14 |
ファイザー・インク |
２−チオピリミジノン
|
|
US10308615B2
(en)
|
2015-05-29 |
2019-06-04 |
Pfizer Inc. |
Heterocyclic compounds as inhibitors of Vanin-1 enzyme
|
|
CA2989456C
(en)
|
2015-06-17 |
2022-01-04 |
Pfizer Inc. |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
AU2016305590A1
(en)
|
2015-08-13 |
2018-02-15 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds
|
|
PT3341367T
(pt)
|
2015-08-27 |
2021-04-19 |
Pfizer |
Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4
|
|
WO2017037567A1
(en)
|
2015-09-03 |
2017-03-09 |
Pfizer Inc. |
Regulators of frataxin
|
|
JP2018531923A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
|
|
WO2017051303A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
|
|
EP3353174A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
|
|
GEP20207147B
(en)
|
2015-12-29 |
2020-09-10 |
Pfizer |
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
|
|
CA3021140A1
(en)
|
2016-04-19 |
2017-10-26 |
Ureka Sarl |
Peptide-oligourea foldamer compounds and methods of their use
|
|
BR112019000589A2
(pt)
|
2016-07-14 |
2019-04-24 |
Pfizer Inc. |
pirimidina carboxamidas como inibidores da enzima vanina-1
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
WO2019133445A1
(en)
|
2017-12-28 |
2019-07-04 |
Inception Ibd, Inc. |
Aminothiazoles as inhibitors of vanin-1
|
|
CR20210110A
(es)
|
2018-08-31 |
2021-05-13 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
|
|
WO2020102575A1
(en)
|
2018-11-16 |
2020-05-22 |
Inception Ibd, Inc. |
Heterocyclic aminothiazoles and uses thereof
|
|
WO2020163689A1
(en)
|
2019-02-08 |
2020-08-13 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
20-hete formation inhibitors
|
|
ES3039586T3
(en)
|
2019-05-20 |
2025-10-22 |
Pfizer |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
CN110922372A
(zh)
*
|
2019-11-04 |
2020-03-27 |
天津大学 |
达格列净的氨基酸共晶物及其制备方法
|
|
JP7711074B2
(ja)
|
2020-02-07 |
2025-07-22 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環ｇｌｐ－１アゴニスト
|
|
EP4154880A4
(en)
*
|
2020-05-21 |
2024-06-05 |
Shionogi & Co., Ltd |
MEDICINES FOR THE TREATMENT OF FATTY LIVER DISEASE
|
|
EP4490155A1
(en)
|
2022-03-09 |
2025-01-15 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
CN121002014A
(zh)
|
2022-12-15 |
2025-11-21 |
加舒布鲁姆生物公司 |
具有glp-1激动剂活性的化合物的盐和固体形式
|